Alps Group Inc.

ALPS Healthcare Biotechnology

Alps Group Inc.’s revenue for fiscal 2026 (year ended March 2026) was $4.9 million, up 44.1% from fiscal 2025.

EPS
−609.4%
Free cash flow
−26.5%

Quarter to September 2025, against a year earlier

0.33 0.02 +6.45%
Market cap
$52.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
−1.64
Dividend safety
n/a
Mar '26 Sep '25 Jun '25 Mar '25 Older periods
Current Ratio
— 0.04 0.25 0.01

+8 more quarters

Net Debt/EBITDA
— 5.50 (0.31) 0.00
Debt/Equity
— 0.00 0.00 0.00
Free Cash Flow per Share
— (0.07) (0.08) (0.05)
Book value per Share
— (3.53) (3.40) (3.09)
Free Cash Flow
— (0.25) (0.27) (0.16)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026